Catalyst Pharmaceuticals Inc (CPRX) Stock Analysis

Catalyst Pharmaceuticals Inc (CPRX) is a publicly traded company in the HEALTHCARE sector. It trades at $31.27, carries a market capitalization of $3.83B, a price-to-earnings ratio of 18.08. This page summarizes the public market data, fundamentals, and frequently asked questions for CPRX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Catalyst Pharmaceuticals Inc currently has a Neutral sentiment score of -0.08.

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in Coral Gables, Florida, specializing in the development and commercialization of innovative therapies for rare neuromuscular and chronic neurological diseases. The company is dedicated to addressing significant unmet medical needs in the United States through a targeted treatment portfolio that aims to improve the quality of life for patients with debilitating conditions often neglected by conventio...

GNG Research Analysis

GNG Research scores Catalyst Pharmaceuticals Inc (CPRX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CPRX.

Frequently Asked Questions

Does CPRX pay dividends?

Catalyst Pharmaceuticals Inc (CPRX) does not currently pay a regular dividend.

What is CPRX's P/E ratio?

Catalyst Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 18.08.

What is CPRX's market cap?

Catalyst Pharmaceuticals Inc (CPRX) has a market capitalization of $3.83B with a current stock price of $31.27.